Drug Profile
Miltefosine - Endo International
Alternative Names: D 18506; HePC; Hexadecylphosphocholine; HPC; Impavido; Miltefosin; MiltexLatest Information Update: 09 Feb 2023
Price :
$50
*
At a glance
- Originator Baxter Oncology; Zentaris
- Developer AEterna Zentaris GmbH; Knight Therapeutics; MegaPharm Ltd; Profounda
- Class Antineoplastics; Antiparasitics; Phospholipids; Quaternary ammonium compounds
- Mechanism of Action Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cancer metastases; Cutaneous leishmaniasis; Leishmaniasis; Visceral leishmaniasis
- No development reported Chagas disease
- Discontinued Acanthamoeba infections; Malignant melanoma
Most Recent Events
- 09 Feb 2023 Discontinued - Preclinical for Acanthamoeba infections in USA (unspecified route)
- 08 Nov 2021 Miltefosine - Endo International receives Orphan Drug status for Invasive candidiasis in USA
- 28 Jan 2021 No recent reports of development identified for preclinical development in Acanthamoeba-infections in USA